Dacomitinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-DACOMITINIB |
|---|---|
| Type | Drug |
| Aliases | VizimproДакомітініб |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | 2nd-generation EGFR TKI (irreversible) |
|---|---|
| Mechanism | Irreversible pan-HER TKI. ARCHER 1050: superior PFS + OS vs gefitinib in 1L EGFR-mut metastatic. Pre-osimertinib alternative. |
| Typical dosing | 45 mg PO once daily. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Niche role; osimertinib is the modern 1L. Listed for completeness.
Used By
No reverse references found in the YAML corpus.